GREAT MINDS
THINK DIFFERENTLY

With a collective wealth of industry success, knowledge, and drive, our leaders share a passion for reinvigorating healthcare.

SCOTT TARRIFF

Founder, Chief Executive Officer and Director

  • Scott Tarriff Founder, Chief Executive Officer and Director

    Scott leads Eagle with more than 25 years of industry experience. Scott founded Eagle in 2007 with the objective of utilizing the 505(b)(2) pathway to maximize the potential of proven medicines. Prior to founding the company, Scott held several key executive-level positions at publicly traded companies, including Bristol-Myers Squibb and Par Pharmaceutical. Scott quickly rose through the ranks at Bristol-Myers Squibb prior to joining Par. While at Par, he served as President and Chief Executive Officer from 2003 to 2006 and served on the board of directors from 2002 to 2006.

    Scott currently sits on the board of directors of Synthetic Biologics, Inc.,  Hackensack Meridian Health, and Hackensack University Medical Center. He previously served on the board of directors of Clinical Data, Inc., a publicly traded pharmaceutical company, from 2009 to 2011, during its acquisition by Forest Laboratories, Inc.

    In 2016, Scott was awarded the prestigious Ernst and Young Entrepreneur Of The Year® Award in the Specialty Pharmaceutical category, New Jersey. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in areas such as innovation, financial performance, and personal commitment to their businesses and communities.

    Scott holds a BS in marketing from Pennsylvania State University and an MBA from Rider College.

DAVID PERNOCK

President, Chief Operating Officer

  • David Pernock President, Chief Operating Officer

    David has been our President and Chief Operating Officer since January 2017. David brings a wealth of pharmaceutical and biotechnology experience to the Eagle leadership team, having previously served as a member of the board from April 2015 through December 2016. David’s strategic focus and entrepreneurial spirit has contributed to the commercial success of many products throughout his distinguished career.

    Before joining Eagle, David served as Chairman of the board of directors and CEO (2010-2017) of Fibrocell Science, Inc., a publicly traded autologous cell and gene therapy company.

    David previously held various positions at GlaxoSmithKline, most notably serving as Senior Vice President of the Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care, and HIV Divisions. He also served as President of Reliant Pharmaceuticals and as a director of Martek Biosciences Corporation.

    David holds a BS in business administration from Arizona State University.

BRIAN CAHILL

Chief Financial Officer

  • Brian Cahill Chief Financial Officer

    Brian was promoted to Chief Financial Officer at Eagle in October 2020, after serving as VP of Finance and Corporate Controller. Brian is a finance and accounting professional with more than 20 years of public company and public accounting experience. His expertise spans financial management, team building, financial reporting in SEC companies, mergers and acquisitions and corporate income tax.

    Before joining Eagle, Brian has held positions of increasing responsibilities with PricewaterhouseCoopers LLP and Par Pharmaceutical Companies, Inc.

    Brian is a Certified Public Accountant and earned a BS in Accounting from Manhattan College.

JUDITH NG-CASHIN, MD

Executive Vice President, Chief Medical Officer

  • Judith NG-CASHIN, MD Executive Vice President, Chief Medical Officer

    Judith Ng-Cashin joined Eagle in October 2020 as Executive Vice President, Chief Medical Officer. She is an accomplished pharmaceuticals executive and brings more than 17 years of industry experience, with expertise in clinical strategy and drug development across large pharmaceutical companies, contract research organizations (“CROs”), and small biotech entities.

    Dr. Ng-Cashin earned a BS in Psychology and a BA in Mathematics from Duke University, and a Doctor of Medicine degree from Rush Medical College.

DANIEL O’CONNOR

Chief Strategy Officer
Head of Corporate Development

  • Daniel O’Connor Chief Strategy Officer
    Head of Corporate Development

    Dan is our Chief Strategy Officer and Head of Corporate Development. Dan served as Finance Director from 2011 to May 2013, and has held multiple roles at Eagle during his tenure.

    Prior to joining Eagle in 2007, Dan held a variety of management positions, such as Senior Analyst at Ethicon (a Johnson & Johnson Company subsidiary) and Lead Finance Liaison throughout Ethicon’s joint venture with Omrix Biopharmaceuticals. Dan additionally held several finance positions at Ranbaxy Pharmaceuticals Inc. (a wholly owned subsidiary of Ranbaxy Inc.), which markets generic products in the US.

    Dan holds a BS in business administration from West Virginia University and an MBA from Rutgers University.

MICHAEL MORAN

Executive Vice President
Sales, Business Development
and Government Affairs

  • Michael Moran Executive Vice President
    Sales, Business Development
    and Government Affairs

    Mike joined Eagle in January 2016 as Vice President, Sales and was promoted to Executive Vice President, Sales, Business Development and Government Affairs in August 2019.  Mike has a lengthy record of success in the pharmaceutical industry.  Prior to joining Eagle, Mike held various positions with increasing responsibility at GlaxoSmithKline, Reliant Pharmaceuticals, Muro and Astra Zeneca.

    Mike earned his B.S. in Business Management from the State University of New York at Empire and completed the Transformational Leadership for Executives program at the University of Pennsylvania Wharton School of Business.

JOHN KIMMET

Executive Vice President,
Marketing for Oncology and Acute Care

  • JOHN KIMMET Executive Vice President
    Marketing for Oncology and Acute Care

    John joined Eagle in August 2020 as Executive Vice President, Marketing for Oncology and Acute Care. Prior to joining Eagle, he held an executive role at Celgene / Bristol Myers Squibb and spent 17 years in Marketing and Operations between Verizon and Vodafone.

    John holds a Master’s in Business Analytics from NYU, a Global Executive MBA from the Fuqua School of Business at Duke University and a Marketing degree from the University of Phoenix.

BOARD OF
DIRECTORS

MICHAEL GRAVES

Chairman of the Board
Executive Committee Chair
Nominating and Corporate Governance Committee Chair
Compensation Committee Chair

  • Michael Graves Chairman of the Board
    Executive Committee Chair
    Nominating and Corporate Governance Committee Chair
    Compensation Committee Chair
    Audit Committee

    Mike has served as a member of Eagle’s board of directors since 2013. Mike is Chairman of the board of directors of Nanocopoeia, Inc., and a member of the board of directors of RiboCor, Inc. Mike has a wide variety of pharmaceutical industry experience including his position as CEO and President of Paddock Laboratories, Inc., and multiple leadership positions leading to President of the Generic Products Division at Par Pharmaceutical from 1998 to 2006.

SCOTT TARRIFF

Chief Executive Officer
Board Member
Executive Committee

  • Scott Tarriff BOD Chief Executive Officer, Board Member, Executive Committee

    Scott leads Eagle with more than 25 years of industry experience. Scott founded Eagle in 2007 with the objective of utilizing the 505(b)(2) pathway to maximize the potential of proven medicines. Prior to founding the company, Scott held several key executive-level positions at publicly traded companies, including Bristol-Myers Squibb and Par Pharmaceutical. Scott quickly rose through the ranks at Bristol-Myers Squibb prior to joining Par. While at Par, he served as President and Chief Executive Officer from 2003 to 2006 and served on the board of directors from 2002 to 2006.

    Scott currently sits on the board of directors of Synthetic Biologics, Inc.,  Hackensack Meridian Health, and Hackensack University Medical Center. He previously served on the board of directors of Clinical Data, Inc., a publicly traded pharmaceutical company, from 2009 to 2011, during its acquisition by Forest Laboratories, Inc.

RICHARD A. EDLIN, J.D.

Board Member, Compensation Committee,
Nominating and Corporate Governance Committee

  • Richard A. Edlin, J.D. Board Member
    Compensation Committee
    Nominating and Corporate Governance Committee

    Rich is currently the Vice Chair, Chair of Litigation Practice in New York and the Business & Regulatory Financial Services Litigation Group, and a member of the Executive Committee of the law firm Greenberg Traurig, LLP.

    Rich is a member of the Board of Trustees of the Urban Justice Center; a member of the Board of Directors for Judges and Lawyers Breast Cancer Alert (JALBCA); a member of the Board of Governors of Hackensack University Medical Center; a trustee of The Carnegie Council for Ethics in International Affairs; a member of the Board of Governors, American Friends of Tel Aviv University; a member of the Economic Club of New York; a fellow of the Litigation Council of America; and a trustee of SEEDS – Access Changes Everything, among other professional and community activities.

ROBERT L. GLENNING

Board Member, Audit Committee, Nominating
and Corporate Governance Committee

  • Robert L. Glenning Board Member
    Audit Committee
    Nominating and Corporate Governance Committee

    Bob has over 30 years of experience in the healthcare industry and currently serves as President of the Financial Services and Information Technology Divisions and CFO at Hackensack Meridian Health, the most comprehensive healthcare delivery network in the state of New Jersey. He previously served as Executive Vice President and CFO of Hackensack University Health Network. From 2002 to 2007, Bob served as EVP and CFO of Kaleida Health, Inc. Prior to Kaleida Health, he served as VP and CEO of Acute Care at Northeast Health and Albany Memorial Hospital. Robert began his career at PricewaterhouseCoopers.

     

STEVEN RATOFF

Board Member, Audit Committee Chair, Compensation Committee

  • Steven Ratoff Board Member
    Audit Committee Chair
    Compensation Committee

    Steve has served as a member of our board of directors since Eagle’s inception in 2007. From 2010, he has served as President and Chief Executive Officer of NovaDel Pharma, Inc., filling a number of executive positions since joining their board of directors in 2005, and is currently serving as its Chairman. Prior to NovaDel, Steve held various executive positions with Cima Labs, Inc., MacroMed, Inc., and Brown-Forman Corporation. In 2004, Steve began his ongoing tenure as a venture partner of ProQuest Investments.

JENNIFER SIMPSON, PhD

Board Member, Nominating and
Corporate Governance Committee

  • JENNIFER SIMPSON, PhD Board Member
    Nominating and Corporate Governance Committee

    Dr. Simpson is the President and CEO of Panbela Therapeutics as of July 2020. She previously served as President and CEO of Delcath, 2015-2020.

    Prior to Delcath, Dr. Simpson served in positions of increasing responsibility at ImClone Systems (a subsidiary of Eli Lilly and Company), most recently as Vice President, Global Marketing, Oncology Brand Lead, where she was responsible for product commercialization activities and launch preparation for one of their late stage assets. Prior to ImClone, Dr. Simpson was Product Director, Oncology Therapeutics Marketing at Ortho Biotech (now Janssen Biotech), a Pennsylvania-based biotech focused on innovative solutions in immunology, oncology and nephrology.

    Early in her career, she spent over a decade as a hematology/oncology nurse practitioner and educator. Dr. Simpson earned a Ph.D. in Epidemiology from the University of Pittsburgh, an M.S. in Nursing from the University of Rochester, and a B.S. in Nursing from the State University of New York at Buffalo.

LUCIANA BORIO, MD

Board Member

  • Luciana Borio, MD Board Member

    Dr. Borio has served as Senior Vice President of In-Q-Tel, an independent strategic investment firm that supports the mission of the United States national security community, since 2019, and served as a member of President Biden’s Transition COVID-19 Advisory Board from November 2020 to January 2021. Dr. Borio also currently serves as a Senior Fellow for Global Health at the Council on Foreign Relations and on the Scientific Advisory Board of Codagenix, Inc. Previously, Dr. Borio served as Director, Medical and Biodefense Preparedness Policy, for the White House National Security Council from 2017 to 2019. Prior to that, Dr. Borio spent nearly ten years at the United States Food and Drug Administration in roles of increasing responsibility, serving as Acting Chief Scientist from 2015 to 2017, Assistant Commissioner for Counterterrorism Policy from 2010 to 2017, Director of the Office of Counterterrorism and Emerging Threats from 2010 to 2015 and Medical Officer from 2008 to 2010. Dr. Borio earned an M.D. with distinction from George Washington University School of Medicine and a B.S. in Zoology from George Washington University.